# Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis

> **NCT03139136** · PHASE2 · COMPLETED · sponsor: **Modern Biosciences Ltd** · enrollment: 121 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MBS2320
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03139136
- **Lead sponsor:** Modern Biosciences Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-30
- **Primary completion:** 2018-11-16
- **Final completion:** 2019-08-13
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03139136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03139136, "Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03139136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*